These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 23841733)
1. Case records of the Massachusetts General Hospital. Case 21-2013. A 68-year-old man with metastatic melanoma. Sullivan RJ; Lawrence DP; Wargo JA; Oh KS; Gonzalez RG; Piris A N Engl J Med; 2013 Jul; 369(2):173-83. PubMed ID: 23841733 [No Abstract] [Full Text] [Related]
3. Response to MAPK pathway inhibitors in BRAF V600M-mutated metastatic melanoma. Parakh S; Murphy C; Lau D; Cebon JS; Andrews MC J Clin Pharm Ther; 2015 Feb; 40(1):121-3. PubMed ID: 25382067 [TBL] [Abstract][Full Text] [Related]
4. Therapeutic Effectiveness of Immunoradiotherapy on Brain-metastatic BRAF/MEK Inhibitor-resistant Melanoma with Balloon Cell Change. Goto H; Shimauchi T; Fukuchi K; Yokota N; Koizumi S; Aoshima M; Endo Y; Masuda Y; Miyazawa H; Kasuya A; Nakamura K; Ito T; Tokura Y Acta Derm Venereol; 2019 May; 99(6):612-613. PubMed ID: 30673109 [No Abstract] [Full Text] [Related]
5. The Blood Brain Barrier and BRAF inhibitors: Implications for patients with melanoma brain metastases. Smalley KSM; Forsyth PA Pharmacol Res; 2018 Sep; 135():265-267. PubMed ID: 29146209 [No Abstract] [Full Text] [Related]
6. MAP kinase activity supported by BRAF (V600E) mutation rather than gene amplification is associated with ETV1 expression in melanoma brain metastases. Birner P; Berghoff AS; Dinhof C; Pirker C; Capper D; Schoppmann SF; Petzelbauer P; von Deimling A; Berger W; Preusser M Arch Dermatol Res; 2014 Dec; 306(10):873-84. PubMed ID: 25073704 [TBL] [Abstract][Full Text] [Related]
7. Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study. Dummer R; Goldinger SM; Turtschi CP; Eggmann NB; Michielin O; Mitchell L; Veronese L; Hilfiker PR; Felderer L; Rinderknecht JD Eur J Cancer; 2014 Feb; 50(3):611-21. PubMed ID: 24295639 [TBL] [Abstract][Full Text] [Related]
8. A new standard of care for metastatic melanoma? Sharma SP Lancet Oncol; 2015 Jan; 16(1):e8. PubMed ID: 25638559 [No Abstract] [Full Text] [Related]
9. Is it good or bad to find a BRAF mutation? Flaherty KT J Clin Oncol; 2011 Apr; 29(10):1229-30. PubMed ID: 21343552 [No Abstract] [Full Text] [Related]
10. [Treatment of patients with brain metastases from a melanoma]. Modesto A; Chira C; Sol JC; Lubrano V; Boulinguez S; Pagès C; Sibaud V; Gomez-Roca C; Moyal É; Meyer N Cancer Radiother; 2019 Apr; 23(2):147-150. PubMed ID: 30904418 [TBL] [Abstract][Full Text] [Related]
11. Lymph node metastases of melanoma: challenges for BRAF mutation detection. Chen G; Dudley J; Tseng LH; Smith K; Gurda GT; Gocke CD; Eshleman JR; Lin MT Hum Pathol; 2015 Jan; 46(1):113-9. PubMed ID: 25456393 [TBL] [Abstract][Full Text] [Related]
12. Cutaneous manifestations of vemurafenib therapy for metastatic melanoma. Owen JL; Lopez IE; Desai SR J Drugs Dermatol; 2015 May; 14(5):509-10. PubMed ID: 25942671 [TBL] [Abstract][Full Text] [Related]
13. A Case of Giant Primary Dermal Melanoma with BRAF V600E Mutation. Imamura T; Nakamura Y; Teramoto Y; Sato S; Asami Y; Arai E; Yamamoto A Acta Derm Venereol; 2016 Aug; 96(6):840-1. PubMed ID: 26984828 [No Abstract] [Full Text] [Related]
14. BRAF mutation analysis of only one metastatic lesion can restrict the treatment of melanoma: a case report. Richtig E; Schrama D; Ugurel S; Fried I; Niederkorn A; Massone C; Becker JC Br J Dermatol; 2013 Feb; 168(2):428-30. PubMed ID: 22775439 [No Abstract] [Full Text] [Related]
15. Vemurafenib as neoadjuvant treatment for unresectable regional metastatic melanoma. Koers K; Francken AB; Haanen JB; Woerdeman LA; van der Hage JA J Clin Oncol; 2013 Jun; 31(16):e251-3. PubMed ID: 23569313 [No Abstract] [Full Text] [Related]
16. Usefulness of immunocytochemistry for the detection of the BRAF(V600E) mutation in circulating tumor cells from metastatic melanoma patients. Hofman V; Ilie M; Long-Mira E; Giacchero D; Butori C; Dadone B; Selva E; Tanga V; Passeron T; Poissonnet G; Emile JF; Lacour JP; Bahadoran P; Hofman P J Invest Dermatol; 2013 May; 133(5):1378-81. PubMed ID: 23303445 [No Abstract] [Full Text] [Related]